Page 71 - Read Online

Page 160 Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11

27. Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683-
8. DOI PubMed
28. Girardin FR, Poncet A, Blondon M, et al. Monitoring white blood cell count in adult patients with schizophrenia who are taking
clozapine: a cost-effectiveness analysis. Lancet Psychiatry 2014;1:55-62. DOI
29. Fabrazzo M, Prisco V, Sampogna G, et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: A
retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res 2017;256:275-82. DOI
30. Üçok A, Çikrikçili U, Karabulut S, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant
schizophrenia. Int Clin Psychopharmacol 2015;30:290-5. DOI
31. John AP, Ko EKF, Dominic A. Delayed initiation of clozapine continues to be a substantial clinical concern. Can J Psychiatry
2018;63:526-31. DOI PubMed PMC
32. Varghese M T, Jyothi KS, Shaji KS, Rita Venugopal L. Delaying clozapine: how long is too long? Gen Psychiatr 2020;33:e100172.
DOI PubMed PMC
33. Verbelen M, Lewis CM. How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis? Pharmacogenomics
2015;16:915-7. DOI PubMed
34. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a
systematic review and meta-analysis. Can J Psychiatry 2017;62:772-7. DOI PubMed PMC
35. Shah P, Iwata Y, Brown EE, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant
schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020;270:11-22. DOI
36. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997;14:1-20. DOI PubMed
37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med 2009;6:e1000097. DOI PubMed PMC
38. Islam F, Hain D, Lewis D, et al. Pharmacogenomics of clozapine-induced agranulocytosis: a systematic review and meta-analysis.
Pharmacogenomics J 2022;22:230-40. DOI PubMed PMC
39. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in
Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8. DOI PubMed
40. Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is
associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995;86:3835-40. PubMed
41. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood
1995;86:1177-83. PubMed
42. Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in
two different ethnic groups. Blood 1997;89:4167-74. PubMed
43. Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-
DQB1*0201. Int J Neuropsychopharmacol 1998;1:41-4. DOI
44. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J
Immunogenet 1998;25:11-3. DOI
45. Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens
2003;62:483-91. DOI
46. Lahdelma L, Ahokas A, Andersson LC, et al. Mitchell B. Balter award. human leukocyte antigen-A1 predicts a good therapeutic
response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol 2001;21:4-7. DOI
47. Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I. Further evidence of human leukocyte antigen-encoded
susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001;11:135-41. DOI PubMed
48. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues
for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007;7:325-32. DOI
49. van der Weide K, Loovers H, Pondman K, et al. Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a
Dutch psychiatric population. Pharmacogenomics J 2017;17:471-8. DOI
50. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with
clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72:458-63. DOI
51. Legge SE, Hamshere ML, Ripke S, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-
associated neutropenia. Mol Psychiatry 2017;22:1502-8. DOI PubMed PMC
52. Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.
Nat Commun 2014;5:4757. DOI PubMed PMC
53. Saito T, Ikeda M, Mushiroda T, et al. Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese
population. Biol Psychiatry 2016;80:636-42. DOI
54. Eap CB, Bender S, Sirot EJ, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2
gene. J Clin Psychopharmacol 2004;24:214-9. DOI
55. Balibey H, Basoglu C, Lundgren S, et al. CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with
schizophrenia. Bull Clin Psychopharm 2011;21:93-9. DOI
56. de Brito RB, de Carvalho Araújo L, Diniz MJA, et al. The CYP1A2 -163C > A polymorphism is associated with super-refractory
schizophrenia. Schizophr Res 2015;169:502-3. DOI